Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

July 6, 2018: By Jon Swedien

Two recent studies have confirmed that Elsalys Biotech’s first-in-class anti-CD160 antibody, ELB01101, is a potential therapeutic for neovascular eye diseases, France-based Elsalys reported July 2.

ELB01101 is intended to engage CD160 and induce cell death of endothelial cells that surround newly formed blood vessels, blocking their formation.

The first study showed that CD160 endothelial expression in retinal vessels was significantly higher in patients with neovascular diseases, and it correlates with a wide range of ocular neovascular diseases.

The second study also showed ELB01101, in relevant animal models, demonstrated a therapeutic benefit alone and in combination with anti-VEGF agents. Elsalys said the antiangiogenic effect of the combination treatment was significantly higher than either antibody alone, suggesting that the anti-CD160 may act independently of the VEGF pathway and could be a good alternative for patients that poorly respond to an anti-VEGF treatment.

The studies were published in the Investigative Ophthalmology & Visual Science.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023